Riskpilot← Back to searchSign inGet full accessNarkosläkare Peter Bengtsson AB
ABActiveOrg 5590345012Myrmalmsvägen 3Medical specialists activities · NACE 8622Est. 20151 employees
Revenue 2025
SEK 128K
+211% vs 2024
EBITDA margin
67.3%
+499% vs 2024
Equity ratio
61.7%
Financial strength
Net profit 2025
SEK 68K
+648% vs 2024
| Revenue | SEK 128K | +211% |
| EBITDA | SEK 86K | +499% |
| Net profit | SEK 68K | +648% |
| Total assets | SEK 192K | +21% |
| Equity | SEK 118K | +47% |
| Employees | 1 | — |
Legal name
Narkosläkare Peter Bengtsson AB
Org number
5590345012
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
11 november 2015
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-10-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget kommer att bedriva narkosläkarverksamhet inom offentlig och privat vård. Verksamheten kan inkludera estetisk såväl som medicinsk vård, handel med medicinskteknisk utrustning och därmed förenlig verksamhet.
Address
Myrmalmsvägen 3
Email
bengtsson.peter70@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 84 | 238 | 0 | 41 | 128 |
| Staff expenses | — | — | — | −3 | −9 |
| EBITDA | 70 | 203 | −25 | 14 | 86 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | 70 | 203 | −25 | 14 | 86 |
| Net financials | −4 | 2 | — | −0 | 1 |
| Profit before tax | 54 | 154 | −4 | 14 | 87 |
| Tax | −8 | −32 | −0 | −5 | −19 |
| Net profit | 46 | 122 | −4 | 9 | 68 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 144 | 314 | 164 | 158 | 192 |
| Equity | 92 | 172 | 92 | 80 | 118 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 41 | 79 | 28 | 34 | 30 |
| Total debt | 41 | 79 | 28 | 34 | 30 |
EBITDA margin
67.3%
This company
15.8%
Market median
+326% vs market
20212025
Equity ratio
61.7%
This company
38.2%
Market median
+62% vs market
20212025
Return on equity
57.4%
This company
18.4%
Market median
+212% vs market
20212025
Net profit margin
53.2%
This company
8.1%
Market median
+557% vs market
20212025
Asset turnover
0.66×
This company
1.12×
Market median
-41% vs market
20212025
Debt / equity
0.62×
This company
0.62×
Market median
+0% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-11-01 – 2025-10-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-11-01 – 2024-10-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-11-01 – 2023-10-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-11-01 – 2022-10-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-11-01 – 2021-10-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2021 | |
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Narkosläkare Peter Bengtsson AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bengt Peter Stenerös Bengtsson | Board of Directors | 0 companies |
| Karin Helena Stenerös Bengtsson | Deputy Board Member | 0 companies |
| Eva Ulrika Nibble | Deputy Board Member | 0 companies |